Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - LA JOLLA PHARMACEUTICAL CO | Financial_Report.xls |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
| þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2011
OR
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 0-24274
LA JOLLA PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
| Delaware | 33-0361285 | |
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) | |
| 4370 La Jolla Village Drive, Suite 400 | ||
| San Diego, CA | 92122 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer o | Accelerated filer o | Non-accelerated filer o | Smaller reporting company þ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes o No þ
The number of shares of the registrant’s common stock, $0.0001 par value per share, outstanding at
August 9, 2011 was 54,105,981.
TABLE OF CONTENTS
| ITEM 6. EXHIBITS | ||||||||
| SIGNATURES | ||||||||
| EX-101 INSTANCE DOCUMENT | ||||||||
| EX-101 SCHEMA DOCUMENT | ||||||||
| EX-101 CALCULATION LINKBASE DOCUMENT | ||||||||
| EX-101 LABELS LINKBASE DOCUMENT | ||||||||
| EX-101 PRESENTATION LINKBASE DOCUMENT | ||||||||
Table of Contents
Explanatory Note
The sole purpose of this amendment to our Quarterly Report on Form 10-Q for the period ended June
30, 2011, filed with the Securities and Exchange Commission (the “SEC”) on August 15, 2011 (the
“Form 10-Q”), is to furnish Exhibit 101 to that Form 10-Q which contains the XBRL (eXtensible
Business Reporting Language) Interactive Data File for the financial statements and notes included
in Part I, Item 1 of the Form 10-Q. As permitted by Rule 405(a)(2)(ii) of Regulation S-T, Exhibit
101 was required to be furnished by amendment within 30 days of the original filing date of the
Form 10-Q.
No other changes have been made to the Form 10-Q and the Form 10-Q has not been updated to reflect
events that may have occurred subsequent to the original filing date.
Pursuant to Rule 406T of Regulation S-T, the interactive data files contained in Exhibit 101 are
not deemed filed or part of a registration statement or prospectus for purposes of Sections 11 or
12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of
the Securities Act of 1934, as amended, and otherwise are not subject to liability under these
sections.
| ITEM 6. | EXHIBITS |
| Exhibit | ||||
| Number | Description | |||
| 31.1 | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (1) |
|||
| 31.2 | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (1) |
|||
| 32.1 | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1) |
|||
| 101.INS | XBRL Instance Document |
|||
| 101.SCH | XBRL Taxonomy Extension Schema Document |
|||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
|||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
|||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
|||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
|||
| (1) | Previously filed or furnished, as applicable, as an exhibit to the Company’s Quarterly
Report on Form 10-Q for the period ended June 30, 2011 filed with the SEC on August 15, 2011. |
1
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| La Jolla Pharmaceutical Company |
||||
| Date: September 12, 2011 | /s/ Deirdre Y. Gillespie | |||
| Deirdre Y. Gillespie, M.D. | ||||
| President and Chief Executive Officer (On behalf of the Registrant) |
||||
| /s/ Gail A. Sloan | ||||
| Gail A. Sloan | ||||
| Chief Financial Officer and Secretary (As Principal Financial and Accounting Officer) |
||||
2